The so-called premixed insulin is a combination of rapid-acting, intermediate-acting insulin, or analogues mixed in proportion, such as 30/70 or 50/50, to facilitate clinical application. So, under what circumstances can premixed insulin be considered? 1.Based on the combination of lifestyle and oral hypoglycemic drugs, if the patient’s HbA1c is >7.0% and the postprandial blood glucose is mainly elevated, premixed insulin can be used as the starting treatment; 2.Patients who receive “three short and one long” insulin intensive therapy, after the blood glucose control is stable and the patient’s compliance is poor, in order to reduce the number of insulin injections, premixed insulin can be used instead for daily subcutaneous injections in the morning and half an hour before dinner, The insulin can be injected subcutaneously half an hour before dinner. Some common premixed insulins are as follows: Novaline 30 (refill) is a dual-phase suspension of soluble menthol insulin (fast-acting insulin analogue) and argin menthol insulin (intermediate-acting insulin analogue) in the ratio of 30:70. Novaline 30R (premixed) refill is a dual-phase insulin preparation containing 30% soluble neutral insulin and 70% low-argin zinc insulin suspension. Novalis 50 refill is an insulin analogue, dual-phase menthol insulin suspension. The suspension contains rapid-acting menadione insulin and intermediate-acting menadione insulin (in the ratio of 50:50). Eugenol 70/30 is mainly composed of 30% recombinant human insulin (regular human insulin) and 70% zinc arginine recombinant human insulin (intermediate acting human insulin). Eugenol 50 is a premixed suspension containing 50% lysergic insulin (ultra-short-acting insulin analogue) and 50% arginine zinc lysergic insulin (intermediate-acting insulin analogue). The active ingredient of Gansulin 30R is recombinant human insulin, and the inactive ingredients are glycerol, disodium hydrogen phosphate, phenol, and pharmaceutical fish semen protein. Eugenol 25 is a premixed suspension containing 25% lysergic insulin (ultra-short-acting insulin analogue) and 75% zinc arginine lysergic insulin (NPL, intermediate-acting insulin analogue).